Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma

@inproceedings{Ewald2015VerticalTO,
  title={Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma},
  author={Florian Ewald and Dominik N{\"o}rz and Astrid Grottke and Johanna Bach and Christiane Herzberger and Bianca Thidahan Hofmann and Bjorn A P Nashan and Manfred J{\"u}cker},
  booktitle={Journal of Cancer},
  year={2015}
}
Hepatocellular carcinoma (HCC) is the sixth most common cancer, and the third most common cause of cancer related death worldwide. The multi-kinase inhibitor Sorafenib represents the only systemic treatment option until today, and results from clinical trials with allosteric mTOR inhibitors were sobering. Since the PI3K/AKT/mTOR and RAF/MEK/ERK signaling pathways are frequently upregulated in HCC, we have analyzed the effects of AKT inhibitor MK-2206, MEK inhibitor AZD6244 (ARRY 142886) and… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 15 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 59 REFERENCES

Similar Papers

Loading similar papers…